Press Release
Alpha–Beta Radiopharmaceuticals Market Set to Reach USD 1.76 Billion by 2032
Pune, India, November 14, 2025 – Global Data Route Analytics unveils its latest industry intelligence report, projecting a robust expansion of the Global Alpha- and Beta-Emitter Radiopharmaceuticals Market, which is poised to grow from USD 805 million in 2024 to an estimated USD 1.76 billion by 2032. This reflects a compound annual growth rate (CAGR) of approximately 10.2%, signaling a significant shift towards advanced, personalized cancer therapies and expanding radiopharmaceutical applications across various therapeutic domains.
For a free sample of the report, please contact us here:
Precision Medicine Driving Growth
Alpha- and beta-emitter radiopharmaceuticals are increasingly adopted in targeted cancer treatments, enabling healthcare providers to deliver precise radioactive doses directly to tumor sites with minimal impact on surrounding healthy tissues. Their application is gaining traction beyond oncology, including in cardiovascular and neurological therapies.
Market Segmentation Highlights
- By Component:
- Alpha-Emitter Radiopharmaceuticals
- Beta-Emitter Radiopharmaceuticals
- By Technology:
- Targeted Alpha Therapy (TAT)
- Peptide Receptor Radionuclide Therapy (PRRT)
- Radioimmunotherapy (RIT)
- Other Radiopharmaceutical Technologies
- By Application:
- Oncology
- Cardiovascular Diseases
- Neurological Disorders
- Others
- By Region & Country:
- North America: United States, Canada
- Europe: Germany, United Kingdom, France, Italy, Spain
- Asia Pacific: China, Japan, India, Australia
- Latin America: Brazil, Mexico
- Middle East & Africa: South Africa, Saudi Arabia
For any inquiry related to this report, please click here:
https://globaldatarouteanalytics.com/report/83/global-alpha-beta-radiopharmaceuticals-market/inquiry
Key Industry Players
Leading companies driving innovation in this market include:
Bayer AG, Novartis AG, Advanced Accelerator Applications (AAA), Lantheus Holdings, Inc., Curium Pharma, Jubilant Radiopharma, Ipsen, RadioMedix, Telix Pharmaceuticals, Nordion Inc., Spectrum Pharmaceuticals, and Eckert & Ziegler AG.
Strategic Insights & Regulatory Landscape
The report underscores a favorable regulatory outlook, as governments and health authorities increasingly support the development and clinical use of radiopharmaceuticals. Coupled with ongoing R&D in radionuclide production and targeted delivery technologies, this environment presents lucrative opportunities for both established players and emerging innovators.
Future Outlook
The market’s growth trajectory aligns with global healthcare trends prioritizing precision oncology, minimally invasive therapies, and personalized medicine. With continuous expansion into new indications and regions, the alpha–beta emitter radiopharmaceuticals sector stands at the forefront of next-generation therapeutic innovation.
For discounts related to this report, explore here:
About Global Data Route Analytics
Global Data Route Analytics is a market research and consulting firm that provides businesses with data analysis, market forecasts, and tailored reports across various industries. The company uses advanced data analysis techniques, proprietary data, and an expert team to help clients understand market trends, make informed decisions, and develop strategies. They focus on delivering customized solutions, competitive intelligence, and growth strategies to help businesses succeed in their respective markets.
Media Contact:
Srushti Tungar
Global Data Route Analytics
